Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group - Takeaways - MDSpire

Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group

  • By

  • J Hillengass

  • L A Moulopoulos

  • S Delorme

  • V Koutoulidis

  • J Mosebach

  • T Hielscher

  • M Drake

  • S V Rajkumar

  • B Oestergaard

  • N Abildgaard

  • M Hinge

  • T Plesner

  • Y Suehara

  • K Matsue

  • N Withofs

  • J Caers

  • A Waage

  • H Goldschmidt

  • M A Dimopoulos

  • S Lentzsch

  • B Durie

  • E Terpos

  • August 25, 2017

  • 0 min

Share

  • 1

    Conventional skeletal survey (CSS) has been the standard imaging technique for detecting myeloma bone disease for decades.

  • 2

    Whole-body computed tomography (WBCT) is more sensitive than CSS for detecting skeletal lesions in multiple myeloma patients.

  • 3

    A study involving 212 patients showed that WBCT detected lytic lesions in 54 patients not identified by CSS.

  • 4

    Concerns exist that earlier detection of bone changes by WBCT may not be clinically relevant for treatment decisions.

  • 5

    The study aimed to compare the sensitivities of WBCT and CSS and assess the prognostic relevance of additional lesions detected by WBCT.

Original Source(s)

Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group

  • by J Hillengass, L A Moulopoulos, S Delorme, V Koutoulidis, J Mosebach, T Hielscher, M Drake, S V Rajkumar, B Oestergaard, N Abildgaard, M Hinge, T Plesner, Y Suehara, K Matsue, N Withofs, J Caers, A Waage, H Goldschmidt, M A Dimopoulos, S Lentzsch, B Durie, E Terpos

  • August 25, 2017

Related Content

Differential expression of immune activation markers in T cells from patients with multiple myeloma

This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet

Lilly moves to acquire Kelonia, plus gene therapy for deafness approved

  • April 27, 2026

  • 6 min
This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet

Lilly moves to acquire Kelonia, plus gene therapy for deafness approved

  • April 27, 2026

  • 6 min